510(k) K223921
K223921 is an FDA 510(k) premarket notification submitted by Beckman Coulter, Inc. for the device "Access CEA". The FDA issued a decision of Substantially Equivalent on September 22, 2023. The device falls under product code DHX (System, Test, Carcinoembryonic Antigen), a Class II device regulated under 21 CFR 866.6010. Beckman Coulter, Inc. has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- September 22, 2023
- Date Received
- December 29, 2022
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- System, Test, Carcinoembryonic Antigen
- Device Class
- Class II
- Regulation Number
- 866.6010
- Review Panel
- IM
- Submission Type